Lifestream - Neue Chance nach STTC! - 500 Beiträge pro Seite

[Inkmarker]

Neuer HOTSTOCK: LIFESTREAM TECHNOLOGIES (LFTC/634814)

Der Wert wurde zuletzt (im letzten Jahr) tüchtig ausgebombt. Der Kurs ging von $ 0,135 auf $ 0,01 zurück. Zuletzt konnte sich schon wieder erholen, und steht nach dem plus von 30% gestern schon wieder bei $ 0,039.

Hier könnte es ähnlich wie bei Softnet (STTC) laufen, denn auch bei LFTC sind die Firmenumsätze im letzten Jahr gestiegen, ohne dass sich dies bisher im Kurs entsprechend niedergeschlagen hat.

Das Allerbeste ist aber: Die Dezemberumsätze, also die vom Weihnachtsgeschäft, sind noch nicht bekanntgegeben wurden. Sollte diese sich ähnlich gut entwickelt haben, wie die Umsätze des letzten halben Jahres könnte es zu einer Kursexplosion kommen.

Mein Tipp: Einstieg noch vor der Bekanntgabe der Zahlen!

[connyco]

Ich stimme Inkmarker zu, der Kurs kam allerdings von 0,25 € im Herbst 2003 herunter. Damals hatten die "hochgradigen Spezialisten vom OBB" einen Run auf mindestens 0,60 € prognostiziert; somit konnte man den Absturz eigentlich erwarten. Ich habe mich damals auch blenden lassen, inzwischen allerdings meinen Einstand mehrmals reduziert. Trotzdem brauche ich mind. 0,08 € um 0 auf 0 rauszukommen.
Ich hoffe also auf das Gesundheitsbewußtsein der AMI`s und die entsprechende Werbetrommel drüben. Hier liegt m.E. auch der Hund begraben !!! Die LFTC`ler sollten sich an Farinella von STTC eine Scheibe abschneiden. Dann steht einer steten Kursverbesserung -gute Zahlen vorausgesetzt- nichts im Wege.

[Inkmarker]

Der Aufwärtstrend setzt sich auch heute fort:

Kurs: $ 0,040 + 2,56%
bid: $ 0,040
ask: $ 0,042

Da geht noch einiges!

[Inkmarker]

So jetzt sind wir auf Tageshoch: $ 0,042 + 7,69%

[haassii]

mein Tip heute

+ 25% Schlußkurs also 0,05 Dollar

[Inkmarker]

Na für die $ 0,05 hat es gestern noch nicht ganz gereicht; denke aber, dass es nächste Woche weiter aufwärts geht.

Wenn wir über $ 0,05 gehen sollte auch der Abwärtstrend des letzten Jahres gebrochen sein.

[ustrading]

habe LFTC schon länger im Depot. Das größte Problem bei Lifestream ist die ständige Ausgabe neuer Aktien. (2004 waren es ca. 50Mio. - wir sind inzwischen bei 200Mio. ausstehenden Aktien und 750Mio. registrierten Shares)

Hier noch ein interessanter Artikel der den Kurs in den letzten 2Tagen nach oben getrieben hat.

The FDA Schedules Hearing On Over-the-Counter Petition for Cholesterol Lowering Drug
Thursday January 6, 6:30 am ET

POST FALLS, Idaho--(BUSINESS WIRE)--Jan. 6, 2005--Lifestream Technologies, Inc. (OTCBB:LFTC - News), a leading supplier of cholesterol monitors, fully supports government and industry efforts to curb cardiovascular disease through proven methods by giving more control of preventive healthcare decisions to individuals. The FDA will be considering a petition to make certain statin lowering drugs available as over-the-counter medications at a hearing scheduled for January 13 and 14, 2005, in Washington, D.C.

After years of assessing the value of statin drugs in lowering cholesterol, along with supporting lifestyle changes, the FDA has agreed to hear a major pharmaceutical company`s petition to move its statin drug from a prescriptive to a non-prescriptive status at retail stores," said Christopher Maus, Lifestream`s CEO. "In a previous hearing, the FDA comments addressed the consumer`s ability to know and track their cholesterol number. If the FDA finds that this statin drug is suitable for non-prescriptive consumer use, Lifestream sees a significant opportunity that could open the floodgates for monitoring cholesterol at home or at the point of care. This increased awareness for regular monitoring would be most conducive in supporting all cholesterol lowering programs through positive feedback and, thus, the greater likelihood of compliance."

"We look forward to supporting the efforts of individuals, industry, government and healthcare providers in their efforts to control the number one cause of premature death in the country," Maus continued. "Those efforts can be greatly served by consumers monitoring their cholesterol with the Lifestream home cholesterol monitor."

[Inkmarker]

#7!

Es sind zwar 20.000k an Aktien ausgegeben, aber ein Großteil der Aktien scheint in festen Händen zu sein, wie sich am durchschnittlichen Handelsvolumen zeigt.

Des Weiteren ist auch nicht damit zu rechnen, dass in nächster Zeit weitere Aktien auf den Markt kommen, da die Wandelschuldverschreibungen bis September 2006 laufen und zudem die Firmenumsätze in den letzten Monaten deutlich gestiegen sind.

LFTC wird zur Zeit mit $ 8.000k bewertet. Wenn man berücksichtigt, dass LFTC im Jahre 2004 den 40. Platz unter den am schnellsten wachsenden Firmen in Nordamerika belegt hat, ist m.E. eine deutlich höhere Mk gerechtfertigt.

Ich könnte mir gut vorstellen, dass Kurs bei positiven Nachrichten betreffend des Weihnachtsgeschäfts in Richtung $ 0,10 marschiert.

Grüße Inkmarker

[Inkmarker]

Um mal einen Vergleich zu STTC anzustellen: Hier beträgt die Mk mit 22.000k fast das Dreifache von LFTC, obwohl die Wachstumsraten beider Unternehmen vergleichbar sind.

Im Unterschied zu STTC wurde LFTC nur das letzte Mal vor gut einem Jahr vom obb empfohlen.

[Inkmarker]

Na mal schauen, ob wir nächste Woche in Richtung $ 0,05 laufen. Dies sollte realisischer Weise drin sein.

[dirkmuc]

Welche Wachstumsraten? Oder kann ich nicht richtig gucken?
Im Moment sehe ich immense Verluste pro Quartal, wobei sich die Kosten eher konstant verhalten und die Kosten fuer Entwicklung und Forschung nicht erhoehen.
Woher dieser Optimismus? Was bietet das Unternehmen fundamental?

Schoene Woche noch euch allen..

[Inkmarker]

#11!

Unternehmensmeldungen insofern:

- 15.12.2004: Preventive Cholesterol Screening Reimbursed by Medicare; Lifestream Technologies sees increased demand for its products

- 21.10.2004: Lifestream Technologies Announces First Quarter FY2005 Shipments Increased 108%; Retailers continue to build inventory and sales

- 13.10.2004: Lifestream Technologies Announces August Shipments Grew 124%

- 06.10.2004: Lifestream Technologies Number One Selling Item in Its Category on National Shopping Network; No. 1 Best Selling Item in Healthy Living Aids During the 24-Hour Period of Airing

- 30.09.2004: Lifestream Technologies Announces July Shipments Grew 169%; Numbers for July 2004 Indicate Lifestream Exceeds Shipment Goals


Daher meine positive Stimmung.


Grüße Inkmarker

[Inkmarker]

Kurs momentan: $ 0,04
bid: $ 0,04
ask: $ 0,042
high: $ 0,043

Mein Wochenziel von $ 0,05 steht noch!

[Inkmarker]

Es geht weiter!

Schlusskurs: $ 0,043
bid: $ 0,043
ask: $ 0,046
high: $ 0,046

Könnte mir gut vorstellen, dass da was kommt, und sich schon mal einige eindecken (nur so eine Vermutung).

Auf jeden Fall war das mal ein guter Wochenauftackt.

[Inkmarker]

Knacken wir heute die $ 0,05-Marke?

Sieht jedenfalls ganz gut aus!

[connyco]

Gestern wieder 10% im Minus, hoffentlich war die leichte Erholung kein Strohfeuer ! ! !
Die stark übergewichtigen Ami`s müssten doch langsam merken, dass in diesem Markt --Cholesterindatenfeststellungen und Reaktion hierauf-- ein immenses Potential steckt.
Hier gibt es ja keinen Markt, nur Reaktion auf OTC.

[Inkmarker]

Abwarten!

Wenn die Zahlen vom Dezembergeschäft kommen, kann es schnell um 50 - 100% nach oben gehen.

[Inkmarker]

N E W S :

Lifestream`s CEO to Testify at FDA Hearing Considering Over-the-Counter Petition for Cholesterol Lowering Drugs; Maus to Testify on the Impact of Home Cholesterol Testing



POST FALLS, Idaho--(BUSINESS WIRE)--Jan. 13, 2005--Lifestream Technologies, Inc. (OTCBB:LFTC), a leading supplier of cholesterol monitors, is scheduled to testify at the FDA hearing considering an over-the-counter petition for cholesterol lowering drugs. Christopher Maus will address the Nonprescription Drugs Advisory Committee (NDAC) and the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) during the public comment period on Friday morning, January 14.

"Lifestream`s home cholesterol monitor can have a material impact in the FDA`s consideration of this petition," said Maus. "I look forward to this opportunity to address any testing concerns the FDA may have, as the benefit of home testing on an individual`s effort to take control by personal health management is acknowledged. With Lifestream`s affordable, easy and accurate suite of testing products, it is well positioned to support the public`s desire to take control of their cholesterol levels. We support government and industry efforts to give more control of preventive health care decisions to individuals."

"Lifestream`s new cholesterol monitor with Health Risk Assessment takes testing one step further by giving an individual the ability to understand combined risk factors and the effects those factors may have on their heart health as defined in the NCEP ATP III guidelines," Maus stated. "Recently cleared by the FDA, Lifestream`s cholesterol monitor with HRA supports efforts to expand cholesterol management programs. The NCEP ATP III recommends home testing as an important tool for individuals as part of their professional healthcare program. Regardless of an individual`s choice of lifestyle changes or the use of prescriptive or non-prescriptive therapies, monitoring cholesterol is a key factor for meaningful outcomes."

About Lifestream Technologies

The Company developed and currently markets a line of cholesterol monitors to consumers and healthcare professionals that provide test results in three minutes.

In addition to the professional monitor, the Company`s product line aids the health conscious consumer in monitoring their risk of heart disease. By regularly testing cholesterol at home, individuals can monitor the benefits of their diet, exercise and/or drug therapy programs. Monitoring these benefits can support the physician and the individual`s efforts to improve compliance. Lifestream`s products also integrate a smart card reader further supporting compliance by storing test results on an individual`s personal health card for future retrieval, trend analysis and assessment.

Lifestream`s monitors are affordable, hand-held devices that provide users with accurate results in less than three minutes. The product line has been designed to accommodate The Data Concern(TM) Personal Health Card(R) allowing multiple users the ability to store their personal results. Lifestream`s products are now available in pharmacy and retail outlets nationwide. To find retailers that carry Lifestream`s products, go to "Store Locator" on www.knowitforlife.com or contact Customer Care at 888-954-LIFE. For Company information, visit www.lifestreamtech.com.

This news release includes certain forward-looking statements within the meaning of the safe harbor protections of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, but are not limited to, statements regarding our current business plans, strategies and objectives that involve risks and uncertainties, and in particular statements referring to our expectations for increased market penetration and improved gross margins from our recently introduced second generation consumer monitors and statements regarding our expectations that we can obtain necessary additional financing and investment. These forward-looking statements involve risks and uncertainties that could cause actual results to differ from anticipated results. The forward-looking statements are based on our current expectations and what we believe are reasonable assumptions given our knowledge of the relevant markets; however, our actual performance, results and achievements could differ materially from those expressed in, or implied by, these forward-looking statements. Factors, within and beyond our control, that could cause or contribute to such differences include, among others, the following: the success of our capital-raising and cost-cutting efforts, developing and marketing relatively new medical diagnostic devices, including technological advancements and innovations; consumer receptivity and preferences; availability, affordability and coverage terms of private and public medical insurance; political and regulatory environments and general economic and business conditions; the effects of our competition; the success of our operating, marketing and growth initiatives; development and operating costs; the amount and effectiveness of our advertising and promotional efforts; brand awareness; the existence of adverse publicity; changes in business strategies or development plans; quality and experience of our management; availability, terms and deployment of capital; labor and employee benefit costs; as well as those factors discussed in the post effective amendment No. 1 to our Registration Statement on Form SB-2 filed December 10, 2004, and in "Item 1 -- Business," "Item 6 -- Management`s Discussion and Analysis and Plan of Operations," particularly the discussion under "Risk Factors -- Substantial Doubt as to our Ability to Continue as a Going Concern" and elsewhere in our most recent Annual Report on Form 10-KSB for our fiscal year ended June 30, 2004, filed with the United States Securities and Exchange Commission. Readers are urged to carefully review and consider the various disclosures made by us in this report and in the aforementioned Form 10-KSB, and those detailed from time to time in our other reports and filings with the United States Securities and Exchange Commission that attempt to advise interested parties of the risks and factors that are likely to affect our business.


CONTACT: Lifestream Technologies, Inc.Gerri Vance, 208-457-9409 ext. 1222

SOURCE: Lifestream Technologies, Inc.

[ustrading]

... könnte ja morgen ein großer Tag für LFTC werden, wenn die Maus die FDA überzeugt

[carlo49]

hi
der otc verkauf der produkte wurde, wie ich es verstehe nicht genehmigt, das patienten ärztliche überwachung benötigen.
was spricht für den kauf von lftc?
und was spricht dagegen?
ich bitte um meinungen.
vieln dank

[Chris8888]

@ Carlo,


woher hast du ddiese Infos denn?WQas kam aus der Verhandlung am Freitag raus?Weiß es einer?


LG

[Inkmarker]

@ carlo49!

Ich habe gerade nochmal im Netz gesucht, aber keine entsprechende Information gefunden.

Woher hast Du Deine Info bzw. kannst Du die Meldung mal reinstellen?


Grüße Inkmarker

[ustrading]

also einige bringen hier etwas durcheinander. In der FDA Anhörung ging es um den unbeschränkten freien Verkauf von Cholesterinsenkern - dieser wurde 20:3 abgelehnt. Die von Lifestream angebotenen cholesterol Monitors sind von der FDA schon lange freigegeben. Lifestream hat sich bei einer möglichen uneingeschränkten Freigabe der Medikamente einen weiteren Umsatzschub (Überwachung des Cholesterinspiegels) versprochen, da bei der ärtzlichen Verschreibung die Überwachung des Cholesterinspiegels der Arzt übernimmt und der Patient damit keinen eigenen Überwachsungmonitor benötigt.

http://www.harktheherald.com/modules.php?op=modload&name=New…

[Inkmarker]

Heute mal wieder eine Meldung, die den Kurs allerdings nicht bewegte:

CORRECTING and REPLACING Lifestream Unveils Prototype for New Low Cost Monitor; Concept Product Unveiled at Recent FDA Hearing
POST FALLS, Idaho

Lifestream Technologies, Inc.
Gerri Vance, 208-457-9409 ext. 1221

First graph, first sentence of release, the ticker should read: (OTCBB:LFTC) (sted (AMEX:KFL)).

The corrected release reads:

LIFESTREAM UNVEILS PROTOTYPE FOR NEW LOW COST MONITOR; CONCEPT PRODUCT UNVEILED AT RECENT FDA HEARING

Lifestream Technologies, Inc. (OTCBB:LFTC), a leading supplier of cholesterol monitors, unveiled a concept product at the recent FDA hearing on an over-the-counter petition for cholesterol lowering drug. Lifestream has filed a patent application for its new product that reduces the cost for devices used for both the pharmacy and home testing. The technology under development looks like a computer mouse and embodies Lifestream`s optic module and strip holder but uses a PC for the balance of the functionality.

"Lifestream is continually looking for ways to reduce the cost to our customers, as well as provide greater functionality for consumers and healthcare providers alike," said Christopher Maus, Lifestream`s President and CEO. "We are exploring a prototype product that allows a user to plug a "cholesterol mouse" into their PC with all functions actually performed by the computer hardware. The product`s cost is reduced by eliminating LCD displays, microprocessors and keypads. Since the mouse is connected to the computer for its functionality, i.e., the data tracking software, the Health Risk Assessment, and data storage, information transfer to healthcare providers is quick, easy, transparent and simple. This technology would allow for easy software expansion to minimize the dating of any technology. Along with weighing this product`s value in the marketplace, we are currently evaluating production, features, and if and when the product will debut. Lifestream realizes the impact home testing has on an individual`s efforts to take control of their own health management program, and we look forward to bringing new products to the marketplace when they are determined to be suitable."

About Lifestream Technologies

The Company developed and currently markets a line of cholesterol monitors to consumers and healthcare professionals that provide test results in three minutes.

In addition to the professional monitor, the Company`s product line aids the health conscious consumer in monitoring their risk of heart disease. By regularly testing cholesterol at home, individuals can monitor the benefits of their diet, exercise and/or drug therapy programs. Monitoring these benefits can support the physician and the individual`s efforts to improve compliance. Lifestream`s products also integrate a smart card reader further supporting compliance by storing test results on an individual`s personal health card for future retrieval, trend analysis and assessment.

Lifestream`s monitors are affordable, hand-held devices that provide users with accurate results in less than three minutes. The product line has been designed to accommodate The Data Concern(TM) Personal Health Card(R) allowing multiple users the ability to store their personal results. Lifestream`s products are now available in pharmacy and retail outlets nationwide. To find retailers that carry Lifestream`s products, go to "Store Locator" on www.knowitforlife.com or contact Customer Care at 888-954-LIFE. For Company information, visit www.lifestreamtech.com.

This news release includes certain forward-looking statements within the meaning of the safe harbor protections of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, but are not limited to, statements regarding our current business plans, strategies and objectives that involve risks and uncertainties, and in particular statements referring to our expectations for increased market penetration and improved gross margins from our recently introduced second generation consumer monitors and statements regarding our expectations that we can obtain necessary additional financing and investment. These forward-looking statements involve risks and uncertainties that could cause actual results to differ from anticipated results. The forward-looking statements are based on our current expectations and what we believe are reasonable assumptions given our knowledge of the relevant markets; however, our actual performance, results and achievements could differ materially from those expressed in, or implied by, these forward-looking statements. Factors, within and beyond our control, that could cause or contribute to such differences include, among others, the following: the success of our capital-raising and cost-cutting efforts, developing and marketing relatively new medical diagnostic devices, including technological advancements and innovations; consumer receptivity and preferences; availability, affordability and coverage terms of private and public medical insurance; political and regulatory environments and general economic and business conditions; the effects of our competition; the success of our operating, marketing and growth initiatives; development and operating costs; the amount and effectiveness of our advertising and promotional efforts; brand awareness; the existence of adverse publicity; changes in business strategies or development plans; quality and experience of our management; availability, terms and deployment of capital; labor and employee benefit costs; as well as those factors discussed in the post effective amendment No. 1 to our Registration Statement on Form SB-2 filed December 10, 2004, and in "Item 1 - Business," "Item 6 - Management`s Discussion and Analysis and Plan of Operations," particularly the discussion under "Risk Factors - Substantial Doubt as to our Ability to Continue as a Going Concern" and elsewhere in our most recent Annual Report on Form 10-KSB for our fiscal year ended June 30, 2004, filed with the United States Securities and Exchange Commission. Readers are urged to carefully review and consider the various disclosures made by us in this report and in the aforementioned Form 10-KSB, and those detailed from time to time in our other reports and filings with the United States Securities and Exchange Commission that attempt to advise interested parties of the risks and factors that are likely to affect our business.





Copyright © 2005 Business Wire. All reproduction, other than for an individual user`s reference, is prohibited without prior written permission.
News Copyright © 2005 Interest!ALERT All rights reserved.